News

Formulation innovation sharing, chemistry frontiers at PharmaCon2018

  • Categories:Company News
  • Author:admin
  • Origin:
  • Time of issue:2018-11-05
  • Views:0

(Summary description)The two-day PharmaCon 2018 4th China International Chemical Drug R&D Forum was held in Suzhou on November 1-2.

Formulation innovation sharing, chemistry frontiers at PharmaCon2018

(Summary description)The two-day PharmaCon 2018 4th China International Chemical Drug R&D Forum was held in Suzhou on November 1-2.

  • Categories:Company News
  • Author:admin
  • Origin:
  • Time of issue:2018-11-05
  • Views:0

1

The two-day PharmaCon 2018 4th China International Chemical Drug R&D Forum was held in Suzhou on November 1-2.

The summit gathered more than 300 leaders from leading chemical drug researchers, enterprises and drug regulatory agency officials from home and abroad to explore common challenges and problems faced by domestic and international pharmaceutical companies, such as policies and regulations, R&D technologies and development trends, and to exchange new developments and trends, in the hope of providing new thinking that can be drawn on for the future development of the industry.

1

The conference aims to provide an in-depth analysis of the domestic and international chemical drug development environment. The two days are divided into four sessions: a session on chemical drug regulations, a session on drug chemical discovery and synthesis, a session on CMC quality research and control, and a session on novel formulations and drug delivery systems.

1

Pan Huiping, Director of Formulation Department of CGeneTech (Suzhou, China) Co., Ltd., as a keynote speaker in the Novel Formulations and Drug Delivery Systems session, shared the strategy of developing new and improved drugs in flash release formulations, which boosted the enthusiasm of participants in the Novel Formulations and Drug Delivery Systems session of the conference.11

 

With the continuous reform of the review and approval system, a series of initiatives such as the speed of review and approval of innovative drugs, the pilot drug listing licensee system and the optimization of the drug review and approval process have been rapidly promoted, which have greatly improved the efficiency of review and approval, and the environment for chemical drug innovation has been significantly improved and the accessibility of innovative products has been enhanced.

PharmaCon provides the most top-notch conference platform for Chinese chemical companies and promotes the exchange and progress of the overall industry.

The

The listing application of Shengshi Tyco's new hypoglycemic drug Shenggliptin was accepted

Today, Shengshi Tyco has accepted the marketing application (NDA) of Shenggliptin, a DPP-4 inhibitor, submitted to the National Drug Administration (NMPA) for the treatment of type 2 diabetes.
2023-02-02
Quantity

"Quantity" Half Achieves Double Prosperity: Tyco's Class 1 New Hypoglycemic Drug Shenggliptin Uncovers Blindness Data

Today, Shengshi Tyco has completed a key clinical study on a class 1 new hypoglycemic drug under development: phase III clinical trial of DPP-4 inhibitor shenggliptin in the treatment of type 2 diabetes. A dose of 50mg can reach the preset end point of the trial. A therapeutic dose of "half the dose" will further improve the safety of this drug and is expected to become the best hypoglycemic drug in the same class.
2022-10-17

Contact Us

Add:Room 101, Bld C11, 218 Xinghu Rd,Suzhou industrial Park,China, 215123

Tel: +86-512-62956960(Recruitment)

         +86-512-62956961(marketing)

Copyright © 2022  CGeneTech (Suzhou, China) Co., Ltd.  All rights reserved.  苏ICP备2022006552号-1  Powered by 300.cn  SEO